Literature DB >> 24938176

Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies.

Matthias Oelke1, Richard Berges, Sandra Schläfke, Martin Burkart.   

Abstract

PURPOSE: To determine the effects of the herbal fixed-dose combination PRO 160/120 (extracts from saw palmetto fruits and stinging nettle roots) on nocturnal voiding frequency, as measured by question 7 of the IPSS questionnaire, in patients with moderate-to-severe LUTS/BPH after 24 weeks of treatment compared to placebo, to the α-blocker tamsulosin, or to the 5α-reductase inhibitor finasteride.
METHODS: The study is about post hoc evaluation of four published randomized, double-blind clinical trials on PRO 160/120, two compared with placebo, one with finasteride and one with tamsulosin. In addition, a pooled data analysis of the two placebo-controlled trials was conducted.
RESULTS: We analyzed data from a total of 922 patients with a mean age of 66 years and a mean baseline nocturnal voiding frequency of 2.1. In the pooled analysis of placebo-controlled trials, nocturnal voids improved by 0.8 (29 %) with PRO 160/120 compared to 0.6 (18 %) with placebo (p = 0.015, Wilcoxon test, one-tailed). The 69 % responder rate to PRO 160/120 was significantly superior to the placebo response (52 %; p = 0.003, χ (2)-test, two-tailed). The majority of responders improved by 1 void/night. Absolute improvements and response rates were consistently higher with PRO 160/120 than with placebo over a range of baseline nocturnal voiding frequencies. There were no differences between PRO 160/120 and finasteride or tamsulosin regarding absolute improvement of nocturnal voids or responds rates.
CONCLUSION: PRO 160/120 significantly improved nocturnal voiding frequency compared to placebo and similar to tamsulosin or finasteride.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24938176     DOI: 10.1007/s00345-014-1338-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

1.  The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Philip van Kerrebroeck; Paul Abrams; David Chaikin; Jenny Donovan; David Fonda; Simon Jackson; Poul Jennum; Theodore Johnson; Gunnar Lose; Anders Mattiasson; Gary Robertson; Jeff Weiss
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study.

Authors:  Haruo Nakagawa; Kaijun Niu; Atsushi Hozawa; Yoshihiro Ikeda; Yasuhiro Kaiho; Kaori Ohmori-Matsuda; Naoki Nakaya; Shinichi Kuriyama; Satoru Ebihara; Ryoichi Nagatomi; Ichiro Tsuji; Yoichi Arai
Journal:  J Urol       Date:  2010-08-19       Impact factor: 7.450

3.  [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study].

Authors:  J Sökeland; J Albrecht
Journal:  Urologe A       Date:  1997-07       Impact factor: 0.639

4.  Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin.

Authors:  Udo Engelmann; Carola Walther; Boris Bondarenko; Petra Funk; Sandra Schläfke
Journal:  Arzneimittelforschung       Date:  2006

5.  Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies.

Authors:  Andreas Eisenhardt; Tim Schneider; Francisco Cruz; Matthias Oelke
Journal:  World J Urol       Date:  2014-01-18       Impact factor: 4.226

Review 6.  Serenoa repens for benign prostatic hyperplasia.

Authors:  James Tacklind; Roderick Macdonald; Indy Rutks; Judith U Stanke; Timothy J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

7.  Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.

Authors:  Matthias Oelke; Claus G Roehrborn; Carlos D'Ancona; Timothy H Wilson; Ramiro Castro; Michael Manyak
Journal:  World J Urol       Date:  2014-06-06       Impact factor: 4.226

8.  Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells.

Authors:  Francesco Scaglione; Valeria Lucini; Marilou Pannacci; Alessia Caronno; Claude Leone
Journal:  Pharmacology       Date:  2008-10-10       Impact factor: 2.547

9.  Saw palmetto for benign prostatic hyperplasia.

Authors:  Stephen Bent; Christopher Kane; Katsuto Shinohara; John Neuhaus; Esther S Hudes; Harley Goldberg; Andrew L Avins
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

10.  Symptomatic benign prostate hyperplasia: impact on partners' quality of life.

Authors:  Dionisios Mitropoulos; Ioannis Anastasiou; Constantina Giannopoulou; Panagiotis Nikolopoulos; Christos Alamanis; Anastasios Zervas; Constantine Dimopoulos
Journal:  Eur Urol       Date:  2002-03       Impact factor: 20.096

View more
  4 in total

1.  Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.

Authors:  Matthias Oelke; Claus G Roehrborn; Carlos D'Ancona; Timothy H Wilson; Ramiro Castro; Michael Manyak
Journal:  World J Urol       Date:  2014-06-06       Impact factor: 4.226

2.  Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).

Authors:  Richard Berges; Klaus Höfner; Michael Gedamke; Matthias Oelke
Journal:  World J Urol       Date:  2014-08-19       Impact factor: 4.226

3.  Nocturia: state of the art and critical analysis of current assessment and treatment strategies.

Authors:  Matthias Oelke; Erika Adler; Daniela Marschall-Kehrel; Thomas R W Herrmann; Richard Berges
Journal:  World J Urol       Date:  2014-10       Impact factor: 4.226

Review 4.  WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH.

Authors:  Ruth Kirschner-Hermanns; Petra Funk; Nadine Leistner
Journal:  Ther Adv Urol       Date:  2019-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.